🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesSUSTAIN-6 to SELECT — what worked for you? Page 3

SUSTAIN-6 to SELECT — what worked for you?

fiona_VT Sat, Aug 16, 2025 at 4:04 PM 38 replies 1,492 viewsPage 3 of 8
DanielChem_CHI
Senior Member
1,234
5,678
Mar 2024
Chicago, IL
Aug 22, 2025 at 4:49 AM#11
Dr.ObesityMed said:
Steady state is the thing most people miss.

Agreed, though "tolerable" needs defining. A dose you tolerate by eating almost nothing is not tolerated, it is being paid for somewhere else — usually in lean mass, sometimes in adherence three months later.

43 16fiona_VT, denise_HTX, raj_cambridge and 40 others
Reply Quote Save Share Report
sean_dublin
Member
212
890
Nov 2024
Dublin, IE
Aug 24, 2025 at 3:12 PM#12
FDA_TrackerJim said:
The oral formulation has different absorption behaviour and the dose numbers are not interchangeable, which is worth saying out loud because people…

Bookmarking. The distinction being drawn above is the one nobody else makes.

44 17sean_dublin, hannah_MT, Dr.SportsMedIN and 41 others
Reply Quote Save Share Report
mel_PDX
Member
189
890
Dec 2024
Portland, OR
Aug 27, 2025 at 1:34 AM#13
Dr.ObesityMed said:
Steady state is the thing most people miss.

I will push back on the "any working dose is fine" framing. The maintenance evidence sits overwhelmingly at the top studied dose, and the extension data shows regain tracking dose reduction rather than tracking stopping. Holding low is reasonable; pretending it is evidentially equivalent is not.

45 18PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 42 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
PeptideChemSF
Senior Member
1,890
9,012
Jan 2024
San Francisco, CA
Aug 29, 2025 at 11:54 AM#14
fiona_VT said:
Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.
fiona_VT said:
...cardiovascular risk is just another fad...

I understand the skepticism — we've all seen "miracle" weight loss solutions come and go. But consider what makes GLP-1 agonists different:

  • Phase 3 RCTs with thousands of participants (not 20-person pilot studies)
  • Published in NEJM, JAMA, Lancet (not press releases)
  • Replicated across multiple independent research groups
  • Proven cardiovascular and renal benefits beyond weight loss
  • Biological mechanism fully characterized at the receptor level

This isn't a fad — it's a new drug class supported by the highest level of clinical evidence. The comparison to past fads is understandable but inappropriate.

46 19ricardo_MIA, BrianDallas92, labquiet_amy and 43 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Aug 31, 2025 at 10:13 PM#15

Moderator note: reminder that nothing in this thread is medical advice, and that clinical claims need a source. Tagging this one for the weekly digest.

47 20PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 44 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register